Format

Send to

Choose Destination
Nat Rev Cancer. 2015 Apr;15(4):201-15. doi: 10.1038/nrc3907. Epub 2015 Mar 19.

Haematological malignancies: at the forefront of immunotherapeutic innovation.

Author information

1
1] Department of Medical Oncology and the Cancer Vaccine Center, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA. [2] Broad Institute, Cambridge, Massachusetts 02142, USA. [3] Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
2
Department of Medical Oncology and the Cancer Vaccine Center, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.
3
1] Department of Medical Oncology and the Cancer Vaccine Center, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA. [2] Broad Institute, Cambridge, Massachusetts 02142, USA. [3] Bristol-Meyers Squibb, Princeton, New Jersey 08540, USA.

Abstract

The recent successes of cancer immunotherapies have stimulated interest in the potential widespread application of these approaches; haematological malignancies have provided both initial proofs of concept and an informative testing ground for various immune-based therapeutics. The immune-cell origin of many of the blood malignancies provides a unique opportunity both to understand the mechanisms of cancer immune responsiveness and immune evasion, and to exploit these mechanisms for therapeutic purposes.

PMID:
25786696
PMCID:
PMC4511812
DOI:
10.1038/nrc3907
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center